Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, J.R. Vane.
Non-steroidal drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.
Proc Nat Acad Sci, 96 (1999), pp. 7563-7568
[2.]
J.L. Wallace, K.M. Webb, N. Vergnolle.
Inhibition of COX-1 and COX-2 is required for NSAID-induced erosion formation [resumen].
Gastroenterology, 118 (2000), pp. G1227
[3.]
J.L. Wallace, A. Bak, W. McKnight, S. Asfaha, K.A. Sharkey, W.K. Mac-Naughton.
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity [véase editorial].
Gastroenterology, 115 (1998), pp. 101-109
[4.]
US Department of Helath and Human Services. Agency for Health Care Policy and Research. Acute pain management: operative or medical procedures and trauma. Rockville (MD): The agency; 1993. Clinical Practice Guideline N.° 1 AHCPR Publication N.° 92-0023. P 107
[5.]
L.A. García Rodríguez, H. Jick.
Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.
Lancet, 343 (1994), pp. 769-772
[6.]
L.A. García Rodríguez, C.H. Cattaruzzi, M.G. Troncon, L. Agostinis.
Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolack, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs.
Arch Intern Med, 158 (1998), pp. 33-39
[7.]
J.R. Laporte, X. Carné, X. Vidal, V. Moreno, J. Juan.
Upper gastrointestinal bleeding in relation to previous use of analgesic and non-steroidal anti-inflammatory drugs.
Lancet, 1 (1991), pp. 85-89
[8.]
D. Henry, A. Dobson, C. Turner.
Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal antiinflammatory drugs.
Gastroenterology, 105 (1993), pp. 1078-1088
[9.]
W.E. Smalley, W.A. Ray, J.R. Daugherty, M.R. Griffin.
Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons.
Am J Epidemiol, 141 (1995), pp. 539-545
[10.]
J. Hallas, J. Lauritsen, H.D. Villadsen, L.F. Gram.
Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding identifying high-risk groups by excess risk estimates.
Scand J Gastroenterol, 30 (1995), pp. 438-444
[11.]
M.J. Langman, J. Weil, P. Wainwright, D.H. Lawson, M.D. Rawlins, R.F. Logan, et al.
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.
Lancet, 343 (1994), pp. 1075-1078
[12.]
J.M. Hansen, J. Hallas, J.M. Lauritsen, P. Bytzer.
Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making.
Scand J Gastroenterol, 31 (1996), pp. 126-130
[13.]
L.S. Simon, H.T. Hatoum, R.M. Bittman, W.T. Archambault, R.P. Polisson.
Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Fam Med, 28 (1996), pp. 204-210
[14.]
S. Pérez-Gutthann, L.A. García Rodríguez, D.S. Raiford.
Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation.
Epidemiology, 8 (1997), pp. 18-24
[15.]
A. Lanas, E. Bajador, P. Serrano, J. Fuentes, S. Carreño, J. Guardia, et al.
Nitrovasodilators, low-dose aspirin, nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding.
N Engl J Med, 343 (2000), pp. 834-839
[16.]
J.M. Piper, W.A. Ray, J.R. Daugherty, M.R. Griffin.
Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs.
Ann Intern Med, 114 (1991), pp. 735-740
[17.]
J. Weil, M.J. Langman, P. Wainwright, D.H. Lawson, M. Rawlins, R.F. Logan, et al.
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.
Gut, 46 (2000), pp. 27-31
[18.]
M. Imhof, C. Ohmann, A. Hartwig, K.P. Thon, K.J. Hengels, H.D. Roher.
Which peptic ulcers bleed? Results of a case-control study. DUSUK Study Group.
Scand J Gastroenterol, 32 (1997), pp. 131-138
[19.]
A. Lanas, P. Serrano, E. Bajador, F. Esteva, R. Benito, R. Sainz.
Evidence of aspirin use in both upper and lower gastrointestinal perforation.
Gastroenterology, 112 (1997), pp. 683-689
[20.]
S.P. Gutthann, L.A. García Rodríguez, D.S. Raiford.
Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation.
Epidemiology, 8 (1997), pp. 18-24
[21.]
M.R. Griffin, J.M. Piper, J.R. Daugherty, M. Snowden, W.A. Ray.
Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.
Ann Intern Med, 114 (1991), pp. 257-263
[22.]
S. Santolaria, A. Lanas, R. Benito, M.A. Pérez-Aisa, M. Montoro, R. Sainz.
Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users.
Aliment Pharmacol Ther, 13 (1999), pp. 1511-1518
[23.]
C. Aalykke, J.M. Lauritsen, J. Hallas, S. Reinholdt, K. Krogfelt, K. Lauritsen.
Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a casecontrol study.
Gastroenterology, 116 (1999), pp. 1305-1309
[24.]
J.Q. Huang, R.J. Lad, S. Sridhar, K. Sumanac, R.H. Hunt.
H. pylori infection increases the risk of non-steroidal anti-inflammatory drug (NSAID)-induced gastro-duodenal ulceration.
Gastroenterology, 116 (1999), pp. A192
[25.]
W.A. Stack, G.M. Hawkey, J.C. Atherton, R.F. Logan, C.J. Hawkey.
Interaction of risk factors for peptic ulcer bleeding.
Gastroenterology, 116 (1999), pp. A97
[26.]
D.J. Cullen, G.M. Hawkey, D.C. Greenwood, H. Humphreys, V. Shepherd, R.F. Logan, et al.
Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs.
Gut, 41 (1997), pp. 459-462
[27.]
C.Y. Wu, S.K. Poon, G.H. Chen, C.S. Chang, H.Z. Yeh.
Interaction between Helicobacter pylori and nonsteroidal antiinflammatory drugs in peptic ulcer bleeding.
Scand J Gastroenterol, 33 (1998), pp. 234-237
[28.]
A. Pilotto, G. Leandro, F. Di Mario, M. Franceschi, L. Bozzola, G. Valerio.
Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly. A case-control study.
Dig Dis Sci, 42 (1997), pp. 586-591
[29.]
J. Labenz, U. Peitz, H. Köhl, J. Kaiser, P. Malfertheiner, A. Hackelsberger, et al.
Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study.
Ital J Gastroenterol Hepatol, 31 (1999), pp. 110-115
[30.]
T.M. Ng, K.M. Fock, J.L. Khor, E.K. Teo, C.S. Sim, A.L. Tan, et al.
Nonsteroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer.
Aliment Pharmacol Ther, 14 (2000), pp. 203-209
[31.]
C.J. Hawkey.
Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs.
Gut, 46 (2000), pp. 310-311
[32.]
E.K. Li, J.J. Sung, R. Suen, T.K. Ling, V.K. Leung, E. Hui, et al.
Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs.
Scand J Rheumatol, 25 (1996), pp. 42-46
[33.]
A. Pilotto, M. Franceschi, G. Leandro, F. Di Mario, G. Valerio.
The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 951-956
[34.]
A.S. Taha, R.D. Sturrock, R.I. Russell.
Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.
Gut, 36 (1995), pp. 334-336
[35.]
M. Janssen, B.A. Dijkmans, C.B. Lamers, A.H. Zwinderman, J.P. Vandenbroucke.
A gastroscopic study of the predictive value of risk factors for non-steroidal anti-inflammatory drug associated ulcer disease in rheumatoid arthritis patients.
Br J Rheumatol, 33 (1994), pp. 449-459
[36.]
J.G. Kim, D.Y. Graham.
The Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy.
Am J Gastroenterol, 89 (1994), pp. 203-207
[37.]
M. Voutilainen, T. Sokka, M. Juhola, M. Farkkila, P. Hannonen.
Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer.
Scand J Gastroenterol, 33 (1998), pp. 811-816
[38.]
F.K. Chan, J.J. Sung, S.C. Chung, K.F. To, M.Y. Yung, V.K. Leung, et al.
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Lancet, 350 (1997), pp. 975-979
[39.]
H.R. Koelz, W. Bolten, B. Dragosics, J. Labenz, W. Roesch, M. Stolte, et al.
Primary prophylaxis of NSAID-induced gastroduodenal ulcers and dyspepsia in H. pylori (HP)-positive patients: randomized, double-blind, placebo-controlled treatment of HP infection vs. omeprazole [resumen].
Gastroenterology, 118 (2000), pp. 1456
[40.]
G. Bianchi Porro, F. Parente, V. Imbesi, F. Montrone, I. Caruso.
Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users. Response to omeprazole dual therapy.
Gut, 39 (1996), pp. 22-26
[41.]
C.J. Hawkey, Z. Tulassay, L. Szczepanski, C.J. Van Rensburg, A. Filipowicz-Sosnowska, A. Lanas, et al.
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study [véase comentario] [fe de errores publicada en Lancet 1998;352: 1634].
Lancet, 352 (1998), pp. 1016-1021
[42.]
F.K. Chan, J.Y. Sung, R. Suen, Y.T. Lee, W.K. Leung, V.K. Leung, et al.
Eradication of H. pylori versus maintenance acid suppression to prevent recurrent ulcer hemorrhage in high risk NSAID users: A prospective randomized study.
Gastroenterology, 114 (1998), pp. A87
[43.]
C.J. Hawkey, J.A. Karrasch, L. Szczepanski, D.G. Walker, A. Barkun, A.J. Swannell, et al.
For the Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs.
N Engl J Med, 338 (1998), pp. 727-734
[44.]
N.D. Yeomans, Z. Tulassay, L. Juhasz, I. Racz, J.M. Howard, CJ Van Rensburg, et al.
for the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs.
N Engl J Med, 338 (1998), pp. 719-726
[45.]
N.M. Agrawal, D.R. Campbell, M.A. Safdi, N.L. Lukasik, B. Huang, M.M. Haber.
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Arch Intern Med, 160 (2000), pp. 1455-1461
[46.]
L.A. García Rodríguez, A. Ruigómez.
Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed.
Epidemiology, 10 (1999), pp. 228-232
[47.]
A. Lanas, M.T. Arroyo.
Fármacos antisecretores y profilaxis de los efectos secundarios gastrointestinales graves asociados al consumo de antiinflamatorios no esteroides.
Med Clin (Barc), 114 (2000), pp. 57-62
[48.]
P. Ekstrom, L. Carling, S. Wetterhus, P.E. Wingren, O. Anker-Hansen, G. Lundegardh, et al.
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.
Scand J Gastroenterol, 31 (1996), pp. 753-758
[49.]
D. Cullen, K.D. Bardhan, M. Eisner, D.G. Kogut, R.A. Peacock, J.M. Thomson, et al.
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users.
Aliment Pharmacol Ther, 12 (1998), pp. 135-140
[50.]
F.E. Silverstein, D.Y. Graham, J.R. Senior, H.W. Davies, B.J. Struthers, R.M. Bittman, et al.
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med, 123 (1995), pp. 241-249
[51.]
F.K. Chan, J.J.Y. Sung, J.K.Y. Ching, J.C.Y. Wu, Y.T. Lee, W.K. Leung, et al.
Prospective randomized trial of misoprostol plus naproxen versus nabumetone to prevent ulcer haemorrhage in high risk NAID users.
Gastroenterology, 116 (1999), pp. A581
[52.]
EMPHASIS Study Group.
Omeprazole in the long-term prevention of aspirin-and NSAID-induced upper gastrointestinal complications in high risk patients.
Gastroenterology, 116 (1999), pp. A319
[53.]
M. Koch.
Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol.
Ital J Gastroenterol, 31 (1999), pp. S54-S62
[54.]
J.B. Raskin, R.H. White, J.E. Jackson, A.L. Weaver, E.A. Tindall, R.B. Lies, et al.
Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens.
Ann Intern Med, 123 (1995), pp. 344-350
[55.]
J.B. Raskin, R.H. White, R. Jaszewski, M.A. Korsten, T.T. Schubert, J.G. Fort.
Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective double-blind multicenter study.
Am J Gastroenterol, 91 (1996), pp. 223-227
[56.]
D.Y. Graham, R.H. White, L.W. Moreland, T.T. Schubert, R. Katz, R. Jaszewski, et al.
The Misoprostol Study Group. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs.
Ann Intern Med, 119 (1993), pp. 257-262
[57.]
N.M. Agrawal, H.E. Van Kerckhove, L.J. Erhardt, S. Geis.
Misoprostol co-administered with diclofenac for prevention of gastroduodenal ulcers. A one-year study.
Dig Dis Sci, 40 (1995), pp. 1125-1131
[58.]
L. Kam-Chuen, S.K. Lam, W.M. Hui, C.Y. Wong, K.M. Chu, W. Hu, et al.
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in NSAID users [resumen].
Gastroenterology, 118 (2000), pp. 1458
[59.]
P. Rose, B. Huang, N. Lukasik, C. Collis.
Evidence that lansoprazole is effective in preventing NSAID-associated ulcers.
Gastroenterology, 116 (1999), pp. G1293
[60.]
A.S. Taha, N. Hudson, C.J. Hawkey, A.J. Swannell, P.N. Trye, J. Cottrell, et al.
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
N Engl J Med, 334 (1996), pp. 1435-1439
[61.]
N. Hudson, A.S. Taha, R.I. Russell, P. Trye, J. Cottrell, S.G. Mann, et al.
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.
Gastroenterology, 112 (1997), pp. 1817-1822
[62.]
A. Rodríguez de la Serna, M. Díaz Rubio.
Multicenter clinical trial of zinc acexamate in the prevention of nonsteroidal antiinflammatory drug induced gastroenteropathy.
J Rheumatol, 21 (1994), pp. 927-933
[63.]
A. Cohen de Lara, H. Gompel, R. Valiente.
Dos estudios comparativos entre dosmalfato y misoprostol en la prevención de la úlcera gástrica por anti-inflamatorios no esteroideos en pacientes reumáticos.
Drugs Today, 36 (2000), pp. 75-81
[64.]
M. Lazzaroni, M. Sainaghi, G. Bianchi Porro.
Nonsteroidal antiinflammatory drug gastropathy: clinical results with antacids and sucralfate.
Ital J Gastroenterol, 31 (1993), pp. S48-S53
[65.]
A. Walan, J.P. Bader, M. Classen, C. Lamers, D.W. Piper, K. Rutgersson, et al.
Effect of omeprazol and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.
N Engl J Med, 320 (1989), pp. 69-75
[66.]
F.L. Lanza, M.F. Rack, T.J. Simon, H. Quan, J.A. Bolognese, M.E. Hoover, et al.
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
Aliment Pharmacol Ther, 13 (1999), pp. 761-767
[67.]
L. Laine, S. Harper, T. Simon, R. Bath, J. Johanson, H. Schwartz, et al.
A randomized trial comparing the effect of rofecoxib, a cylooxigenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.
Gastroenterology, 117 (1999), pp. 776-783
[68.]
M.J. Langman, D.M. Jensen, D.J. Watson, S.E. Harper, P-L Zhao, J.A. Bolognese.
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA, 282 (1999), pp. 1929-1933
[69.]
L.S. Simon, F.L. Lanza, P.E. Lipsky, R.C. Hubbard, S. Talwalker, B.D. Schwartz, et al.
Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis. A Randomized Controlled Trial.
JAMA, 282 (1999), pp. 1921-1928
[70.]
J.L. Goldstein, N.M. Agrawal, F. Silverstein, J. Kaiser, A.M. Burr, K.M. Verburg, et al.
Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs.
Gastroenterology, 116 (1999), pp. A174
[71.]
J.L. Goldstein, N.M. Agrawal, F. Silverstein, K.M. Verburg, A.M. Burr, R.C. Hubbard, et al.
Influence of H. pylori (HP) infection and/or low dose aspirin (AASA) on gastroduodenal ulceration in patients treated with placebo celecoxib or NSAIDs.
Gastroenterology, 116 (1999), pp. A174
[72.]
C. Hawkey, L. Laine, T. Simon, A. Beaulieu, J. Maldonado-Cocco, E. Acevedo, et al.
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor) ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randommized, double blind, placebo-controlled trial.
Arthritis Rheum, 43 (2000), pp. 370-377
[73.]
P. Emery, H. Zeidler, T.K. Kvien, M. Guslandi, R. Naudin, H. Stead, et al.
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
Lancet, 354 (1999), pp. 2106-2111
[74.]
N.J. Wight, N. Garlick, N. Calder, A. Dallob, P. Wong, J. Cote, et al.
Evidence that the COX-2 specific inhibitor at 50 mg spares gastric mucosal prostaglandin synthesis in human.
Gastroenterology, 118 (2000), pp. G1466
[75.]
I. Bjarnason, G. Sigthorsson, R. Crane, T. Simon, M. Hoover, J. Bolognese, et al.
COX-2 specific inhibition with MK-0966 25 or 50 mg QD does does not increase intestinal permeability: a controlled study with placebo and indometacin 50 mg TID [resumen].
Am J Gastroenterol, 93 (1998), pp. 1670
[76.]
E.G. Smecuol, E. Sugai, H. Vázquez, S.I. Niveloni, Pedreira, R. Mazure, et al.
Acute doses of celecoxib a new specific cyclooxygenase inhibitor, do not affect the overall gut permeability [resumen].
Gastroenterology, 118 (2000), pp. G1449
[77.]
L. Laine, C. Bombardier, C.J. Hawkey, D. Shapiro, A. Reicin.
Influence of H. pylori and other potential risk factors on clinical GI events in a double-blind outcome study of rofecoxib vs. naproxen [resumen].
Gastroenterology, 118 (2000), pp. G4798
[78.]
Truitt K, Ettinger W, Schnitzer T, Greenwald M, Daniels B, Zeng Q et al. Rofecoxib a COX-2 specific inhibitor had clinical efficacy and overall safety in treating osteoarthritis patients 80 years and older. In XIV European League Against Rheumatism Congress, Glasgow: 6-11 de junio de 1999 [resumen n.° 859]
[79.]
M.K. Jones, H. Wang, B.M. Peskar, E. Levin, R.M. Itani, I.J. Sarfeh, et al.
Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
Nat Med, 5 (1999), pp. 1418-1423
[80.]
P. Serrano, A. Lanas, M.T. Arroyo, J.A. Casasnovas, I. Ferreira.
Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low dose aspirin: a cohort study.
Gastroenterology, 118 (2000), pp. A862
[81.]
R. Stalnikowicz-Darvasi.
Gastrointestinal bleeding during lowdose aspirin administration for prevention of arterial occlusive events. A critical analysis.
J Clin Gastroenterol, 21 (1995), pp. 13-16
[82.]
B. Simon, H. Elsner, P. Muller.
Protective effect of omeprazole against low-dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjects.
Arzneimittelforschung, 45 (1995), pp. 701-703
[83.]
P. Muller, W. Fuchs, B. Simon.
Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study.
Arzneimittelforschung, 47 (1997), pp. 758-760
[84.]
A. Lanas, J. Fuentes, R. Benito, E. Bajador, P. Serrano, R. Sainz.
Helicobacter pylori increases the risk of gastrointestinal bleeding in patients taking low dose aspirin.
Gastroenterology, 118 (2000), pp. A252
[85.]
B. Daniels, B. Seidenberg.
Cardiovascular safety profile of rofecoxib in controlled clinical trials. American College of Rheumatology. Annual Scientific Meeting: November 13-17 1999, Boston. Massachussets [resumen 435].
Arthritis Rheum, 42 (1999), pp. S143
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
